Treating depression in patients with cardiovascular disease

Harvard Review of Psychiatry

Volumn 7, Issue 2, 1999, Pages 85-93

  Seiner, Stephen Jay ^a   Mallya, Gopinath ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; ENCAINIDE; FLECAINIDE; FLUDROCORTISONE; FLUOXETINE; IMIPRAMINE; LIDOCAINE; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MORACIZINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTIARRHYTHMIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; HEART INFARCTION; HUMAN; HYPERTENSION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; TACHYCARDIA;

EID: 0032888510     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1093/hrp/7.2.85     Document Type: Review

References (76)

1. Malzberg B. Mortality among patients with involutional melancholia. Am J Psychiatry 1937;93:1231-8.
2. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987;44:473-80.
3. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 1976;33:1029-37.
4. Carney RM, Rich MW, Freedland KE, Saini J, TeVelde A, Simeone C, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627-33.
5. Wassertheil-Smoller S, Applegate WB, Berge K, Chang CJ, Davis BR, Grimm R Jr, et al. Change in depression as a precursor of cardiovascular events. Arch Intern Med 1996;156: 553-61.
6. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-25.
7. Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989;149:1785-9.
8. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
9. Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med 1993;95:23-8.
10. Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990;51(suppl):4-9.
11. Bigger JT Jr, Albrecht P, Steinman RC, Rolnitzky LM, Fleiss JL, Cohen RJ. Comparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction. Am J Cardiol 1989; 64:536-8.
12. Bigger JT Jr, Kleiger RE, Fleiss JL, Rolnitzky LM, Steinman RC, Miller JP. Components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol 1988;61:208-15.
13. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-5.
14. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-7.
15. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990;28:215-22.
16. 2+ response is increased in the blood platelets of depressed patients. Biol Psychiatry 1991;30:310-2.
17. Hillis LD, Lange RA. Serotonin and acute ischemic heart disease. N Engl J Med 1991;324:688-90.
18. Shapiro PA, Lidagoster L, Glassman AH. Depression and heart disease. Psychiatr Ann 1997;27:347-52.
19. Pollock BG, Laghrissi-Thode F, Wagner WR, Finkel M, Johnson PC. Increased PF4 and β-TG in depressed patients with ischemic heart disease [Abstract]. Abstracts for the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1995:121.
20. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-92.
21. Hyman SE, Arana GW, Rosenbaum JF. Handbook of psychiatric drug therapy. 3rd ed. Boston: Little, Brown, 1995.
22. Glassman AH, Bigger JT Jr, Giardina EG, Kantor SJ, Perel JM, Davies M. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979;1:468-72.
23. Vohra J, Burrows G, Hunt D, Sloman G. The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. Eur J Cardiol 1975;3:219-27.
24. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993; 54(suppl):16-22.
25. Stoudemire A, Moran MG, Fogel BS. Psychopharmacology in the medically ill patient. In: Schatzberg AF, Nemeroff CB, eds. American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995; 783-801.
26. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987; 44:273-5.
27. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R. Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients. J Clin Psychiatry 1982;43(5, pt 2):8-15.
28. Burkhardt D, Raeder E, Muller V, Imhof P, Neubauer H. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978;239:213-6.
29. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
30. Glassman AH, Johnson LL, Giardina EG, Walsh BT, Roose SP, Cooper TB, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983;250:1997-2001.
31. Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981;38:815-20.
32. Anonymous. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-12.
33. Anonymous. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327: 227-33.
34. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993;269:2673-5.
35. Anonymous. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988; 61:501-9.
36. Gelenberg AJ. The P450 family. Biol Ther Psychiatry Newslett 1995;18:29-31.
37. Feder R. Bradycardia and syncope induced by fluoxetine [Letter]. J Clin Psychiatry 1991;52:139.
38. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985;46(3, pt 2):42-4.
39. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:660-5.
40. Littman AB. Review of psychosomatic aspects of cardiovascular disease. Psychother Psychosom 1993;60:148-67.
41. Franco-Bronson K. The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am 1996; 19:329-50.
42. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512-6.
43. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-8.
44. Breuel HP, DeLeenheer I, Coninx L, Gammans R. Comparisons of the cardiovascular effects of nefazodone, imipramine, and placebo in healthy elderly volunteers [Abstract]. Eur Neuropsychopharmacol 1993;2(special issue):423.
45. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-9.
46. Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH. Blood pressure effects of phenelzine. J Clin Psychopharmacol 1983;3:307-10.
47. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E. Adverse reactions to monoamine oxidase inhibitors, II: Treatment correlates and clinical management. J Clin Psychopharmacol 1985;5:2-9.
48. Klein DF, Gittelman R, Quitkin F, Rifkin A. Diagnosis and drug treatment of psychiatric disorders: adults and children. 2nd ed. Baltimore: Williams & Wilkins, 1980.
49. Patterson JF. Metoclopramide therapy of MAOI orthostatic hypotension [Letter]. J Clin Psychopharmacol 1987;7:112-3.
50. Mitchell JE, Mackenzie TB. Cardiac effects of lithium therapy in man: a review. J Clin Psychiatry 1982;43:47-51.
51. Ahrens B, Grof P, Möller HJ, Müller-Oerlinghausen B, Wolf T. Extended survival of patients on long-term lithium treatment. Can J Psychiatry 1995;40:241-6.
52. Welch CA, Drop LJ. Cardiovascular effects of ECT. Convuls Ther 1989;5:35-43.
53. Rice EH, Sombrotto LB, Markowitz JC, Leon AC. Cardiovascular morbidity in high-risk patients during ECT. Am J Psychiatry 1994;151:1637-41.
54. Zielinski RJ, Roose SP, Devanand DP, Woodring S, Sackeim HA. Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 1993;150:904-9.
55. Waal HJ. Propranolol-induced depression [Letter]. BMJ 1967; 2:50.
56. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986; 255:357-60.
57. Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol 1996;49:809-15.
58. Patten SB, Williams JV, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996;41:469-76.
59. Carney RM, Rich MW, TeVelde A, Saini J, Clark K, Freedland KE. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. Am J Med 1987;83:223-6.
60. McNeil GN, Shaw PK, Dock DS. Substitution of atenolol for propranolol in a case of propranolol-related depression. Am J Psychiatry 1982;139:1187-8.
61. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 1980;100: 160-78.
62. Giannini AJ, Houser WL Jr, Loiselle RH, Giannini MC, Price WA. Antimanic effects of verapamil. Am J Psychiatry 1984; 141:1602-3.
63. Dubovsky SL, Franks RD, Lifschitz M, Coen P. Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 1982;139:502-4.
64. Dubovsky SL, Buzan RD. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997;58:224-42.
65. Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155:972-3.
66. Höschl C, Kožený J. Verapamil in affective disorders: a controlled, double-blind study. Biol Psychiatry 1989,25:128-40.
67. Hullett FJ, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 1988;145:1277-9.
68. Gajula RP, Berlin RM. Captopril-induced mania [Letter]. Am J Psychiatry 1993;150:1429-30.
69. Mesure G, Fallet A, Chevalier JF. Psychotropic effects of angiotensin-converting enzyme inhibitors: what are the arguments [In French with an English abstract]? Encephale 1995; 21:609-14.
70. Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984;141:110-1.
71. Cohen BM, Zubenko GS. Captopril in the treatment of recurrent major depression [Letter]. J Clin Psychopharmacol 1988; 8:143-4.
72. 3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989;491:136-43.
73. 1 receptors in hippocampal LTP. Pharmacol Biochem Behav 1993;45:455-64.
74. Schleifer SJ, Slater WR, Macari-Hinson MM, Coyle DA, Kahn M, Zucker HD, et al. Digitalis and beta-blocking agents: effects on depression following myocardial infarction. Am Heart J 1991;121:1397-402.
75. Wamboldt FS, Jefferson JW, Wamboldt MZ. Digitalis intoxication misdiagnosed as depression by primary care physicians. Am J Psychiatry 1986;143:219-21.
76. Anonymous. Physicians' desk reference. 51st ed. Oradell, New Jersey: Medical Economics, 1997.